Synchron
Company · Brooklyn, New York, USA
Pioneer of the endovascular BCI: the Stentrode is delivered through the jugular vein into a blood vessel over the motor cortex, avoiding open brain surgery.
Synchron’s Stentrode is a stent-like electrode array implanted through a catheter, similar to procedures used for strokes. It records motor intentions that let people with paralysis text, browse and use smart devices.
Its US COMMAND early feasibility study reported no serious device-related adverse events. In November 2025 Synchron raised a $200 million Series D to fund a pivotal trial, the last step before applying for FDA market approval. The company originated in Melbourne, Australia.
In the news
Synchron raises $200M to run a pivotal trial of its blood-vessel BCI
The Series D funds the study Synchron needs before it can ask the FDA for full market approval of the Stentrode.
Synchron's blood-vessel implant can detect eye movements from brain signals
A Journal of Neural Engineering study in one person with ALS is the first demonstration of an eye-movement BCI using endovascular recordings.